open access

Vol 24, No 3 (2018)
Artykuły
Published online: 2018-10-25
Get Citation

Angioplasty of the popliteal artery using the Jaguar™ stent

Paweł Wojciech Potoczny, Piotr Janik, Adam Uryniak
DOI: 10.5603/AA.2018.0015
·
Acta Angiologica 2018;24(3):80-85.

open access

Vol 24, No 3 (2018)
Artykuły
Published online: 2018-10-25

Abstract

Introduction. The aim of this study was to evaluate the effectiveness of the endovascular
treatment of atherosclerotic stenosis/occlusion of the popliteal artery according to TASC II recommendations
using the Jaguar SM self-expanding stent depending on the modifiable
and unmodifiable risk factors of repeated stenosis/occlusions.

Material and methods. The study included 126 men and 46 women aged 46–95 years in 2011–2015.
Surgeries were performed in the scheduled and emergency mode. Angioplasty of the popliteal artery with
the Jaguar stent implantation was performed in patients with severe chronic limb ischaemia and critical limb
ischaemia. Post-operative popliteal artery patency was evaluated in relation to sex, obesity, diabetes, smoking
tobacco, and patency of the lower extremity arteries.

Results. The postoperative patient follow-up was conducted for 60 months, demonstrating 67% patency after
12 months, 59% patency after 24 months, 53% patency after 36 months, 45% patency after 48 months,
and 31% patency after 60 months.

Conclusions. The Jaguar™ stent implantation is an effective and safe method of treatment of atherosclerotic
stenosis and occlusion of the popliteal artery. The occlusion was found in patients with the risk factors such as:
obesity, diabetes, and tobacco smoking, limited runoff arteries in the lower leg. Stent fracture did not occur in
any patient.

Abstract

Introduction. The aim of this study was to evaluate the effectiveness of the endovascular
treatment of atherosclerotic stenosis/occlusion of the popliteal artery according to TASC II recommendations
using the Jaguar SM self-expanding stent depending on the modifiable
and unmodifiable risk factors of repeated stenosis/occlusions.

Material and methods. The study included 126 men and 46 women aged 46–95 years in 2011–2015.
Surgeries were performed in the scheduled and emergency mode. Angioplasty of the popliteal artery with
the Jaguar stent implantation was performed in patients with severe chronic limb ischaemia and critical limb
ischaemia. Post-operative popliteal artery patency was evaluated in relation to sex, obesity, diabetes, smoking
tobacco, and patency of the lower extremity arteries.

Results. The postoperative patient follow-up was conducted for 60 months, demonstrating 67% patency after
12 months, 59% patency after 24 months, 53% patency after 36 months, 45% patency after 48 months,
and 31% patency after 60 months.

Conclusions. The Jaguar™ stent implantation is an effective and safe method of treatment of atherosclerotic
stenosis and occlusion of the popliteal artery. The occlusion was found in patients with the risk factors such as:
obesity, diabetes, and tobacco smoking, limited runoff arteries in the lower leg. Stent fracture did not occur in
any patient.

Get Citation

Keywords

popliteal artery, balloon angioplasty, endovascular surgery, PTA, Jaguar SM self-expanding stent

About this article
Title

Angioplasty of the popliteal artery using the Jaguar™ stent

Journal

Acta Angiologica

Issue

Vol 24, No 3 (2018)

Pages

80-85

Published online

2018-10-25

DOI

10.5603/AA.2018.0015

Bibliographic record

Acta Angiologica 2018;24(3):80-85.

Keywords

popliteal artery
balloon angioplasty
endovascular surgery
PTA
Jaguar SM self-expanding stent

Authors

Paweł Wojciech Potoczny
Piotr Janik
Adam Uryniak

References (25)
  1. Adam DJ, Bradbury AW. Dokument TASC II w leczeniu chorób tętnic obwodowych. Eur J Vasc Endovasc Surg. 2007 ; 33(1): 1–2.
  2. Komisja ds. Zaleceń: Polskiego Towarzystwa Chirurgii Naczyniowej, Polskiego Towarzystwa Angiologicznego, Polskiego Towarzystwa Flebologicznego, Polskiego Towarzystwa Radiologicznego. Polskie zalecenia wewnątrznaczyniowego leczenia chorób tętnic obwodowych i aorty 2009. Chirurgia Polska. 2009; 11: 1–12.
  3. Wroński J. Zabiegi wewnątrznaczyniowe w chorobach niedokrwiennych kończyn i OUN.
  4. Richter GM, Roeren TH, Loeldge G. Percutaneous Transluminal AnSuperior clinical results of iliac stent placement versus percutaneous transluminal angioplasty: four-yearsgioplasty of the subclavian arteries. Radiology . 1991; 18(Suppl): 161.
  5. Triller J, Walpoth B, Stirnemann P, et al. A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions. CardioVascular and Interventional Radiology. 1992; 15(5): 306–312.
  6. Taylor LM, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg. 1990; 11(2): 193–205; discussion 205.
  7. Bergamini TM, Towne JB, Bandyk DF, et al. Experience with in situ saphenous vein bypasses during 1981 to 1989: determinant factors of long-term patency. J Vasc Surg. 1991; 13(1): 137–47; discussion 148.
  8. Donaldson MC, Mannick JA, Whittemore AD. Femoral-distal bypass with in situ greater saphenous vein. Long-term results using the Mills valvulotome. Ann Surg. 1991; 213(5): 457–64; discussion 464.
  9. Goshima KR, Mills JL, Hughes JD. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J Vasc Surg. 2004; 39(2): 330–335.
  10. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Endorsed by: the European Stroke Organization (ESO). The Task Force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) V. Aboyans, J.B. Ricco, M.E.L. Bartelink, M. Björck, M. Brodmann, T. Coh nert, J.P. Collet, M. Czerny, M. De Carlo, S. Debus, C. Espinola-Klein, T. Kahan, S. Kownator, L. Mazzolai, A.R. Naylor, M. Roffi, J. Röther, M. Sprynger, M. Tendera, G. Tepe, M. Venermo, C. Vlachopoulos, I. Desormais; ESC Scientific Document Group European Heart Journal, 2017; doi: 10,1093/eurheartj/ehx095.
  11. Polish recommendations for intravascular treatment of peripheral artery and aorta diseases – 2009 (Polskie zalecenia wewnątrznaczyniowego leczenia chorób tętnic obwodowych i aorty 2009). Chirurgia Polska . 2009; 11(1): 1–12.
  12. Neil N. Stent fracture in the superficial femoral and proximal popliteal arteries: literature summary and economic impacts. Perspect Vasc Surg Endovasc Ther. 2013; 25(1-2): 20–27.
  13. Laird JR, Katzen BT, Scheinert D, et al. RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010; 3(3): 267–276.
  14. Rabellino M, Zander T, Baldi S, et al. Clinical follow-up in endovascular treatment for TASC C-D lesions in femoro-popliteal segment. Catheter Cardiovasc Interv. 2009; 73(5): 701–705.
  15. Stecko W, Rogala W, Feldo M, et al. Results of endovascular treatment of iliac and femoral symptomatic lesions. Identification of re-intervention risk factors. Acta Angiologica. 2017; 23(3): 115–123.
  16. Brouillet J, Deloose K, Goueffic Y, et al. Primary stenting for TASC C and D femoropopliteal lesions: one-year results from a multicentric trial on 203 patients. J Cardiovasc Surg (Torino). 2018; 59(3): 392–404.
  17. Charakterystyka produktu. http.balton.pl/produkty/kardiologia-i-radiologia/jaguar-stent-samorozprezalny.
  18. Bosiers M, Deloose K, Callaert J, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011; 54(4): 1042–1050.
  19. Kickuth R, Keo HH, Triller J, et al. Initial clinical experience with the 4-F self-expanding XPERT stent system for infrapopliteal treatment of patients with severe claudication and critical limb ischemia. J Vasc Interv Radiol. 2007; 18(6): 703–708.
  20. Laird J, Jaff MR, Biamino G, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. J Vasc Interv Radiol. 2005; 16(8): 1067–1073.
  21. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008; 118(13): 1358–1365.
  22. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008; 358(7): 689–699.
  23. Gammon R. Plaque excision treatment of infrainguinal PAD. Endovascular Today. 2005; 4(6): 70–74.
  24. Zeller T, Krankenberg H, Reimers B, et al. [Initial clinical experience with a new percutaneous peripheral atherectomy device for the treatment of femoro-popliteal stenoses]. Rofo. 2004; 176(1): 70–75.
  25. Recommendation No. 8/2018 of 11th January 2018 of the president of the Agency for Health Technology Assessment and Tariff System concerning the validity of healthcare provision qualification – “Balloon Angioplasty of the Lower Limb Arteries (femoral and popliteal arteries), using drug-eluting balloon”, as a standard agreement health service in terms of hospital treatment. (Rekomendacja nr 8/2018 z dnia 11.stycznia 2018r. Prezes Agencji Oceny Technologii medycznych i Taryfikacji w sprawie zasadności kwalifikacji świadczenia opieki zdrowotnej „ Angioplastyka balonowa tętnic kończyn dolnych ) tętnice udowe i podkolanowe) z wykorzystaniem balonu uwalniającego lek” jako świadczenia gwarantowanego z zakresu leczenia szpitalnego.).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl